Monica N Fornier

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J Esteva
    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 7:R436-43. 2005
  2. ncbi Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
  3. ncbi Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
  4. ncbi Dose-dense adjuvant chemotherapy for primary breast cancer
    Monica Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Breast Cancer Res 7:64-9. 2005
  5. ncbi Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
    M N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Oncol 16:234-9. 2005
  6. ncbi Adjuvant chemotherapy for primary breast cancer
    Monica Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 457, New York, NY 10021, USA
    Curr Oncol Rep 7:18-22. 2005
  7. ncbi Epothilones in breast cancer: review of clinical experience
    M N Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:v16-21. 2007
  8. ncbi Approved agents for metastatic breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Oncol 38:S3-10. 2011
  9. ncbi Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:757-63. 2007
  10. ncbi Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials
    Monica Fornier
    Division of Solid Tumor Oncology, Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 10:352-8. 2010

Detail Information

Publications25

  1. ncbi Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J Esteva
    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 7:R436-43. 2005
    ..We also sought to determine whether early changes in serum HER2/neu concentrations could be a predictor of progression-free survival...
  2. ncbi Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
    ..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
  3. ncbi Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
    ....
  4. ncbi Dose-dense adjuvant chemotherapy for primary breast cancer
    Monica Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Breast Cancer Res 7:64-9. 2005
    ..This finding is highly relevant and has immediate implications for clinical practice...
  5. ncbi Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
    M N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Oncol 16:234-9. 2005
    ..We also examined its predictive value in a cohort of metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel...
  6. ncbi Adjuvant chemotherapy for primary breast cancer
    Monica Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 457, New York, NY 10021, USA
    Curr Oncol Rep 7:18-22. 2005
    ..This overview provides a summary of the state of the art and the most recent developments regarding adjuvant chemotherapy for primary breast carcinoma...
  7. ncbi Epothilones in breast cancer: review of clinical experience
    M N Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:v16-21. 2007
    ..The epothilones are a novel class of antimicrotubule agents that have demonstrated antitumor activity in the setting of resistance...
  8. ncbi Approved agents for metastatic breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Oncol 38:S3-10. 2011
    ..Ongoing research is seeking to improve outcomes in this patient population...
  9. ncbi Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:757-63. 2007
    ..Ixabepilone is likely to be the first available drug in its class, with the potential to bring clinical benefit to patients with a wide range of malignancies...
  10. ncbi Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials
    Monica Fornier
    Division of Solid Tumor Oncology, Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 10:352-8. 2010
    ..This review examined the results of 2 phase III clinical trials of ixabepilone in patients with drug-resistant or heavily pretreated, locally advanced breast cancer or MBC. Patients and..
  11. ncbi Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era
    Shari Damast
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:1105-12. 2010
    ..To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT)...
  12. ncbi Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Pamela Drullinsky
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center at Rockville Centre, 1000 North Village Ave, Rockville Centre, NY 11570, USA
    Clin Breast Cancer 10:440-4. 2010
    ..Randomized trials with other regimens demonstrate that dose-dense (DD) scheduling can offer greater efficacy. We investigated the feasibility of administering CMF using a DD schedule...
  13. ncbi Novel anti-tubulin cytotoxic agents for breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Anticancer Ther 9:175-85. 2009
    ..Elucidating the relative importance of these agents and incorporating them into existing treatment paradigms is a significant challenge for the future...
  14. ncbi Optimizing the use of anthracyclines in older patients with breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 475 New York NY 10065, USA
    Crit Rev Oncol Hematol 77:131-41. 2011
    ..This review will focus on the benefits and risks of anthracyclines in older patients with various subtypes of breast cancer...
  15. ncbi Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines
    Elizabeth A Comen
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:S7-19. 2010
    ..Ultimately, delivering quality of care necessitates balancing an understanding of evidence-based data with sensitive attention to quality-of-life goals...
  16. ncbi Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Adv Hematol Oncol 7:115-22. 2009
    ..Further clinical studies assessing the role of ixabepilone in other settings, as well as the clinical investigation of other epothilones, are eagerly awaited...
  17. ncbi Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    A D Seidman
    Breast Cancer Medicine Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2587-95. 2001
    ..Efficacy was correlated with immunohistochemical and fluorescent in situ hybridization (FISH) assay results...
  18. ncbi Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 70:2768-75. 2012
    ..We investigated N-telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) as potential predictors of ONJ onset...
  19. ncbi Limited overall survival in patients with brain metastases from triple negative breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast J 18:345-50. 2012
    ..This single-institution, retrospective study confirms that the prognosis for patients with BMs from TNBC remains poor. This group of patients urgently needs improved therapies...
  20. ncbi Microtubule active agents: beyond the taxane frontier
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, Breast Cancer Medicine Service, New York, New York 10021, USA
    Clin Cancer Res 14:7167-72. 2008
    ..A variety of other agents that act on the microtubules at different sites with a variety of structures are at varying stages of development...
  21. ncbi Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    M N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:3934-41. 2001
    ..CONCLUSIONS: Dose-dense sequential single-agent chemotherapy is more feasible than doxorubicin with subsequent concurrent paclitaxel and cyclophosphamide...
  22. ncbi Long-term clinical outcomes of whole-breast irradiation delivered in the prone position
    Lauren D Stegman
    Department of Radiation Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 68:73-81. 2007
    ..The aim of this study was to evaluate retrospectively the effectiveness and toxicity of post-lumpectomy whole-breast radiation therapy delivered with prone positioning...
  23. ncbi Risk models for neutropenia in patients with breast cancer
    Chau T Dang
    Breast Cancer Medical Service, Memorial Sloan Kettering, Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:14-20. 2003
    ..These findings could lead to changes in how early-stage breast cancer is managed...
  24. ncbi Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
    M N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:5841-6. 2007
    ..In vivo, docetaxel must precede flavopiridol by at least 4 h to induce this effect. We conducted a phase I trial of weekly, sequential docetaxel followed 4 h later by flavopiridol in patients with advanced solid tumors...
  25. ncbi Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review)
    Enrico Crucitta
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
    Int J Oncol 20:1283-8. 2002
    ..New data on exemestane are forthcoming both in the adjuvant and neoadjuvant setting, which could improve the management of early breast cancer in the future...